Loading…
First Tracks Biotherapeutics, Inc. is projected to rise to $82.78 by 2027, a +73% move from its current price of $47.78. TRAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $44.83 | $47.83 | $51.03 | +0.10% |
| Aug 2 | $43.69 | $47.88 | $52.48 | +0.21% |
| Aug 3 | $42.84 | $47.93 | $53.62 | +0.31% |
| Aug 4 | $42.15 | $47.98 | $54.62 | +0.42% |
| Aug 5 | $41.55 | $48.03 | $55.52 | +0.52% |
| Aug 6 | $41.02 | $48.08 | $56.35 | +0.63% |
| Aug 7 | $40.55 | $48.13 | $57.13 | +0.73% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $40.55 | $48.13 | $57.13 | +0.73% |
| Week 2 | $38.04 | $48.48 | $61.79 | +1.47% |
| Week 3 | $36.29 | $48.84 | $65.73 | +2.22% |
| Week 4 | $34.92 | $49.20 | $69.33 | +2.97% |
| Week 5 | $33.78 | $49.56 | $72.72 | +3.73% |
| Week 6 | $32.80 | $49.92 | $75.99 | +4.49% |
| Week 7 | $31.95 | $50.29 | $79.16 | +5.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs).
First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc.
was founded in 2019 and is based in San Diego, California.
TRAX is the ticker symbol for First Tracks Biotherapeutics, Inc. The asset trades in the healthcare sector with a current price of $47.78 and a market capitalization of $1.67B. It is currently ranked 2042 by market capitalization among listed assets.
The current price is $47.78, reflecting the latest market activity and funding expectations for the company’s clinical-stage immunology portfolio. Forecasts indicate a variable but growth-oriented price path. For 2026, the min is $15.32, the avg is $47.78, and the max is $78.41, with a neutral sentiment and an RSI of 80.
The 30-day range spans from $31.17 to $73.25, suggesting upside potential within a defined trading band. Longer horizons show bullish momentum with substantial upside: 2030 delivers an average of $127.81, 2040 averages to $478.68, and 2050 averages to $820.25, underlining a multi-year uptrend in expected value.
A major floor 88.6% below — a decisive break under it would weaken the trend.
The nearest floor, 66.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 44.3% above — clearing it would confirm fresh momentum.
Key TRAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $41.81 | Buy | $42.81 | Buy |
| MA 10 | $39.56 | Buy | $39.88 | Buy |
| MA 20 | $34.29 | Buy | $35.12 | Buy |
| MA 50 | $23.93 | Buy | $27.80 | Buy |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 82.44 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 151.93 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.73 | Buy |
| ROC (12) | 39.02 | Buy |
| Bollinger %B (20,2) | 0.93 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 3.13 | Buy |
| Awesome (5,34) | 14.40 | Buy |
| Ultimate (7,14,28) | 80.91 | Sell |
| Momentum (10) | 11.57 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 44.77 | Buy |
| ADX (14) | 42.31 | Buy |
| ATR (14) | 1.80 | Info |
The near-term technical picture is described as BULLISH. RSI14 sits at 80, indicating an overbought condition within the current move. The price is anchored by a resistance at $47.78 and a support level at $16.03, with the 30-day range between $31.17 and $73.25.
The 50-day moving average is $23.93, providing a short-term benchmark for momentum versus the recent price action. Traders may watch how the price behaves around the $47.78 resistance as the market digests upcoming catalysts in the biotech space.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.32 | $47.78 | $78.41 | 0% | Neutral | |
| $54.40 | $82.78 | $136.29 | +73% | Bullish | |
| $65.67 | $110.91 | $199.11 | +132% | Bullish | |
| $66.66 | $123.52 | $236.53 | +159% | Bullish | |
| $63.21 | $127.81 | $257.93 | +167% | Bullish | |
| $54.17 | $119.24 | $251.62 | +150% | Bullish | |
| $70.82 | $157.37 | $345.32 | +229% | Bullish | |
| $102.69 | $228.20 | $518.45 | +378% | Bullish | |
| $111.11 | $246.91 | $567.89 | +417% | Bullish | |
| $124.38 | $276.39 | $635.71 | +478% | Bullish | |
| $215.41 | $478.68 | $1,100.97 | +902% | Bullish | |
| $369.11 | $820.25 | $1,886.56 | +16.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.32 | $47.78 | $56.41 | +0.00% |
| August 2026 | $42.95 | $52.55 | $67.28 | +9.99% |
| September 2026 | $41.87 | $52.56 | $69.79 | +0.02% |
| October 2026 | $39.01 | $50.02 | $68.30 | -4.84% |
| November 2026 | $40.14 | $52.37 | $73.14 | +4.71% |
| December 2026 | $41.50 | $55.03 | $78.41 | +5.07% |
Click any year to see its month-by-month TRAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TRAX could reach as high as $78.41, with a base case around $47.78 and support toward $15.32 — roughly 0% from $47.78. Price action looks broadly range-bound.
Expect TRAX to range from $54.40 to $136.29 through 2027. The $82.78 average target implies a +73% move from current prices. That is up +73% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The TRAX price prediction for 2028 points to an average of $110.91 (low $65.67, high $199.11) — a potential gain of +132% on today's $47.78. Momentum favours further upside here.
In 2029, TRAX is projected to trade between $66.66 and $236.53, averaging $123.52 — a potential gain of +159% from today's $47.78. That is up +11% on the projected 2028 average. Buyers look set to stay in control over this stretch.
First Tracks Biotherapeutics, Inc.'s 2030 outlook centres on $127.81, within a $63.21 to $257.93 range. That is up +3% on the projected 2029 average. That marks a +167% change versus current levels. Momentum favours further upside here.
By 2031, TRAX could reach as high as $251.62, with a base case around $119.24 and support toward $54.17 — roughly +150% from $47.78. Buyers look set to stay in control over this stretch.
Expect TRAX to range from $70.82 to $345.32 through 2032. The $157.37 average target implies a +229% move from current prices. That is up +32% on the projected 2031 average. Momentum favours further upside here.
The TRAX price prediction for 2033 points to an average of $228.20 (low $102.69, high $518.45) — a potential gain of +378% on today's $47.78. Buyers look set to stay in control over this stretch.
In 2034, TRAX is projected to trade between $111.11 and $567.89, averaging $246.91 — a potential gain of +417% from today's $47.78. That is up +8% on the projected 2033 average. Momentum favours further upside here.
First Tracks Biotherapeutics, Inc.'s 2035 outlook centres on $276.39, within a $124.38 to $635.71 range. That is up +12% on the projected 2034 average. That marks a +478% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, TRAX could reach as high as $1,100.97, with a base case around $478.68 and support toward $215.41 — roughly +902% from $47.78. Momentum favours further upside here.
Expect TRAX to range from $369.11 to $1,886.56 through 2050. The $820.25 average target implies a +16.2x move from current prices. That is up +71% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRAX today (≈ 20.929259 TRAX) could be worth
$17,167.13
+$16,167.13 (+1617%) by 2050 · US Dollar
Based on the average projected TRAX price of $820.25 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRAXwould be worth at today's price.
$1,000 invested in TRAX on Apr 6, 2026 (≈ 52.631579 TRAX) would be worth
$2,514.74
+$1,514.74 (+151.5%) today · 2.51× · US Dollar
Based on a TRAX entry price of $19 vs. today's $47.78.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $37.64 | $1,269.39 | +26.9% |
| 1 month ago | $20.12 | $2,374.75 | +137.5% |
| 3 months ago | $22.38 | $2,134.94 | +113.5% |
| All time ago | $19 | $2,514.74 | +151.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRAX forecast.
Our base-case forecast reaches $96.00 around 2028.
Implied market cap at $96.00: $3.35B
The multi-year forecast paints a clearly bullish trajectory. In 2027 the average price is expected to be $82.78 with a 73.3% ROI and bullish sentiment, followed by 2028 at $110.91 (132.1% ROI) and 2029 at $123.52 (158.5% ROI). By 2030 the average is projected to $127.81 with a 167.5% ROI and continued bullish momentum.
Further out, the 2032–2035 period shows substantial upside, with 2032 at $157.37 (229.4% ROI) and 2033 at $228.20 (377.6% ROI). The most pronounced gains appear in 2040, with an average of $478.68 and a 901.9% ROI, and in 2050 an average of $820.25 with a 1616.7% ROI, both bullish. These figures are estimates and not guarantees; actual results depend on market dynamics, regulatory factors, and company progress.
Nonetheless, the trajectory implies meaningful upside potential over the coming years while acknowledging inherent uncertainty and volatility in biotech equities.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $127.81 with a min of $63.21 and a max of $257.93, a ROI of 167.5%, and a bullish sentiment.
Forecasts point to bullish sentiment from 2027 onward with rising averages (e.g., $82.78 in 2027, $127.81 in 2030) and significant upside by 2040–2050, but these are estimates, not guarantees, and depend on market and clinical development outcomes.
Yes. The forecasts show the 2028 average at $110.91 and the 2029 average at $123.52, indicating a path that passes $100 in the coming years.
The 2040 forecast shows an average of $478.68 with a min of $215.41 and a max of $1,100.97, and a ROI of 901.9%.
First Tracks Biotherapeutics, Inc. Community Discussion
0Share your First Tracks Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.